Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-18
2006-07-18
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07078433
ABSTRACT:
The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
REFERENCES:
patent: 5821130 (1998-10-01), Baldwin et al.
patent: 5932611 (1999-08-01), Wuthier et al.
patent: 6225340 (2001-05-01), Wuthier et al.
patent: 6660765 (2003-12-01), Wuthier et al.
Abbas et al., “Mycotoxins produced by toxicFusariumisolates obtained from Agricultural and nonagricultural areas (Artic) of Norway,” Mycopathologia 1989; 105:143-51.
Abbas et al., “Production of trichothecene and non-trichothecene mycotoxins byFusariumspecies isolated from maize in Minnesota,” Mycopathologia 1989; 108:55-8.
Brownlee, S., “They called his theory ridiculous,” U.S. New & World Report 1996, p. 82.
Cook et al., “Factors influencing growth plate cartilage turnover,” Poult Sci 1994; 73:889-96.
Haynes et al., “Ultrastructure ofFusarium-induced tibial dyschondroplasia in chickens: a sequential study,” Vet Pathol 1986; 23:499-505.
Kim et al., “Sambutoxin, a new mycotoxin produced by toxicFursariumisolates obtained from rotted potato tubers.” Appl. Environ. Microbiol., 1994, pp. 4380-4386, vol. 60.
Krogh et al., “Natural occurrence of the mycotoxin fusarochromanone, a metabolite ofFusarium equiseti, in cereal feed associated with tibial dyschondroplastic,” Appl Environ Microbiol 1989; 55:3184-8.
Lawler et al., “Acid phosphatase activity of chondroclasts from Fusarium-induced tibial dyschondroplastic cartilage,” Avian Dis 1988; 32:240-5.
Lee et al., “TDP-1, a Toxic Component Causing Tibial Dyschondroplasia in Broiler Chickens, and Trichothecenes fromFusarium roseumGraminearum,” Applied and Environmental Microbiology 1985; p. 102-106.
Minervini et al., “Immunomodulatory effects of fusarochromanones TDP-1 and TDP-2,” Nat Toxins 1992; 1:15-18.
Mirocha et al., “Absence of trichothecenes in toxigenic isolates ofFusarium moniliforme,” App. Environ Microbiol 1990; 56:520-5.
Mirocha et al., “Mycotoxin production byFusarium oxysporumandFusarium sporotrichioidesisolated fromBaccharis spp.from Brazil,” Appl Environ Microbiol 1989; 55:254-5.
Nie, D. et al., “Defect in Formation of Functional Matrix Vesicles by Growth Plate Chondrocytes in Avian Tibial Dyschondroplasia: Evidence of Defective Tissue Vascularization,” Journal of Bone and Mineral Research 1995; 10:1625-1634.
Orth et al., “Avian tibial dyschondroplasia: a morphological and biochemical review of the growth plate lesion and its causes.” Vet Pathol, 1994, pp. 403-414, vol. 31.
Pathre et al., “The structure of fusarochromanone: new mycotoxin fromFusarium roseum, “Graminearum”,” Can. J. Chem. 1986; 64:1308-1311.
Powlosky et al., “Mass spectral analysis and fragment ion structure of fusarochromanone, ”Biol Mass Spectrometry 1991; 20:743-9.
Walser et al., “Effect of dietary selenium on the development of Fusarium-induced tibial dyschondroplasia in broiler chickens,” Avian Dis 1988; 32:84-8.
Wright, Jr. et al., “Effect of fusarochromanone and T-2 toxin on articular chondrocytes in monolayer culture,” Fundam Appl Toxicol 1987; 9:595-7.
Wu et al., “Fusarochromanone production byFusarium isolates,” Appl Environ Microbiol 1990; 56:2989-93.
Wu et al., “Tibial dyschondroplasia of chickens induced by fusarochromanone, a mycotoxin,” Avian Dis., 1993, vol. 37, pp. 302-309.
Xie et al., “Biosynthesis of furachromanone and its monoacetyl derivative byFusarium equiseti,” Appl Environ Microbiol 1989; 55:794-7.
Xie et al., “Isolation and structure identification of two new derivatives of the mycotoxin fusarochromenone produced byFusarium equiseti.” J. Nat. Prod., 1995, pp. 124-127, vol. 58.
Yu et al., “Immunochromatography of fusarochromanone mycotoxins,” J Assoc Off Anal Chem 1991; 74:655-60.
Yu et al., “Production and characterization of antibody against fusarochromanone,” Food & Agricult Immun 1990; 2:55-64.
Nie Daotai
Wuthier Roy E.
Pryor Alton
Senniger Powers
University of South Carolina
LandOfFree
FC101 and analogs as a method of treatment for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with FC101 and analogs as a method of treatment for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FC101 and analogs as a method of treatment for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3585011